Trial reportBritish journal of clinical pharmacology2011
Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren.
Trial report in British journal of clinical pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 90 citations in OpenAlex.
- Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers.European journal of clinical pharmacology · 2014Trial
- Apple juice greatly reduces systemic exposure to atenolol.British journal of clinical pharmacology · 2013Trial
- Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects.European journal of clinical pharmacology · 2012Trial
- Food Additives Inhibit Intestinal Drug Transporters but Have Limited Effect on In Vitro Drug Permeability.Molecular pharmaceutics · 2025Article
- Importance of N-Glycosylation for the Expression and Function of Human Organic Anion Transporting Polypeptide 2B1.ACS pharmacology & translational science · 2023Article
- The Challenge and Importance of Integrating Drug-Nutrient-Genome Interactions in Personalized Cardiovascular Healthcare.Journal of personalized medicine · 2022Review
- Pharmacogenomics Informs Cardiovascular Pharmacotherapy.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Imaging-Based Characterization of aPharmaceutics · 2021Article
- Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.Chemico-biological interactions · 2021Article
- Food-Drug Interactions with Fruit Juices.Foods (Basel, Switzerland) · 2020Review
- Potential Risk of Food-Drug Interactions: Citrus Polymethoxyflavones and Flavanones as Inhibitors of the Organic Anion Transporting Polypeptides (OATP) 1B1, 1B3, and 2B1.European journal of drug metabolism and pharmacokinetics · 2020Article
- Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions.Drug metabolism and disposition: the biological fate of chemicals · 2020Article
- Pharmacokinetic Interactions between Cardiovascular Medicines and Plant Products.Cardiovascular therapeutics · 2019Review
- Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.Clinical pharmacology and therapeutics · 2018Review
- A regulatory science viewpoint on botanical-drug interactions.Journal of food and drug analysis · 2018Review
- Food-drug interactions precipitated by fruit juices other than grapefruit juice: An update review.Journal of food and drug analysis · 2018Review
- Phytotherapeutics: The Emerging Role of Intestinal and Hepatocellular Transporters in Drug Interactions with Botanical Supplements.Molecules (Basel, Switzerland) · 2017Review
- Prioritizing pharmacokinetic drug interaction precipitants in natural products: application to OATP inhibitors in grapefruit juice.Biopharmaceutics & drug disposition · 2017Article
- Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1.Pharmaceutical research · 2014Article
- Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.Drug metabolism and disposition: the biological fate of chemicals · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe aim of this study was to investigate the effects of orange juice and apple juice on the pharmacokinetics and pharmacodynamics of aliskiren.
methodsIn a randomized crossover study, 12 healthy volunteers ingested 200 ml of orange juice, apple juice or water three times daily for 5 days. On day 3, they ingested a single 150-mg dose of aliskiren. Plasma aliskiren concentrations were measured up to 72 h, its excretion into urine up to 12 h and plasma renin activity up to 24 h.
resultsOrange and apple juice reduced aliskiren peak plasma concentrations by 80% (95% CI 63%, 89%, P < 0.001) and 84% (95% CI 72%, 91%, P < 0.001), and the area under the plasma aliskiren concentration-time curve (AUC) by 62% (95% CI 47%, 72%, P < 0.001) and 63% (95% CI 46%, 74%, P < 0.001), respectively, but had no significant effect on its elimination half-life or renal clearance. The decreases in aliskiren AUC by orange and apple juice correlated with aliskiren AUC during the water phase (r= 0.98, P < 0.001). Plasma renin activity was 87% and 67% higher at 24 h after aliskiren during the orange juice and apple juice phases, respectively, than during the water phase (P < 0.05).
conclusionsOrange juice and apple juice greatly reduce the plasma concentrations and renin-inhibiting effect of aliskiren, probably by inhibiting its OATP2B1-mediated influx in the small intestine. Concomitant intake of aliskiren with orange or apple juice is best avoided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.